reactive responses are postulated to occur because of egg-related antigen (measles, mumps, and rubella [MMR] and influenza vaccine), mercury (hepatitis B vaccine, diphtheria, tetanus, pertussis vaccine [DTaP] , Japanese encephalitis vaccine, and influenza vaccine), vaccine stabilizer (MMR), or antibiotics included in the live-attenuated virus vaccine (MMR); however, these mechanisms are not clearly explained, often [1] [2] [3] [4] .
Most vaccines result in local reactions following vaccination such as pain, swelling and redness in some population; this frequency slightly increases following DTaP or tetanuscontaining vaccines [5] . After 2-3 weeks of receiving Bacillus Calmette-Guérin (BCG) vaccine, localized inflammation and ulceration forms, then heal within few months [6] . Systemic reactions such as fever and malaise may occur in some population; the frequency is higher in DTaP, which may also result in irritability and decreased oral intake in infants [7] . Following MMR vaccination, systemic reactions such as measleslike illness due to vaccine-strain virus may occur on more than 5-10% of vaccinees [8] . This vaccine-related measles is generally mild in immune-competent persons; however, may result in severe disease in immune-compromised hosts, therefore MMR and other live-attenuated vaccines are contraindicated in such population. The attenuated mumps virus included in MMR may result arthralgia and lymphadenitis on less than 1% of those who are vaccinated [9] .
Vaccine Safety Management
The advances in vaccines and immunization practices have led to decline in the incidence of vaccine-preventable diseases worldwide. However, the increase in reported cases of AE-FI has been noted recently, probably following increased utilization of vaccines; increased vaccinees who are susceptible to such complications; and increased awareness and notification. In the United States with long-standing history of AE-FI surveillance system, the number of reported AEFI cases has exceeded the number of reported vaccine-preventable diseases; therefore the increase in public awareness on AEFI may occur, consequently [10] .
In order to maintain the public confidence and to ensure political support on National Immunization Program, the public health sector must ensure the safety of vaccines and immunization practices. Before the introduction of AEFI surveillance system in the 1980s, neurologic adverse event such as seizure was reported following whole-cell pertussis vaccination in multiple countries. In response to the media coverage, immunization coverage decreased and then consequent resurgence of pertussis was observed in many countries such as Japan, Sweden, and UK [11, 12] . In the US, lawsuits against vaccine manufacturers has resulted in renunciation of vaccine production, and therefore led to inadequate procurement of essential vaccines [13] .
In order to minimize the unnecessary conflicts and arguments, and to achieve adequate level of immunization coverage in the population, the need for AEFI management system was raised [14] . The national AEFI management system was meant to distinguish between the true vaccine reactions and the coincidental events following immunization in timely manner, therefore to ensure safety of the vaccinees and to improve the confidence in National Immunization Program.
Most of other medications are intended to use for treatment purposes, however, vaccines are given to healthy people, especially children, to prevent the future or potential occurrence of infectious diseases. The unhealthy patients who are receiving the medications such as chemotherapeutic agents or antibiotics may tolerate the occurrence of adverse event. However, the vaccinees, who are mostly healthy without having any diseases, may not tolerate on reactions after they receive the vaccines. Furthermore, vaccines are forcibly given in some instances, therefore high level of safety should be guaranteed. In addition, most vaccines utilized by National Immunization Program are given to general populations in a large amount; therefore safety should be heavily reviewed.
Vaccine Safety Management in Korea
In the Republic of Korea, AEFI management system began since 1994, after the two deaths following Japanese encephalitis vaccine immunization was reported [15] . In 2000, the system that included report of AEFI through Electronic Document Interchange was introduced, and all systems were computerized before 2001. In 2001, the Communicable Disease Control Act has mandated healthcare professionals to report all noticed AEFI to the public health centers, and in 2005, the system has introduced an Internet-based reporting system, which made the reporting more handy. Currently, vaccine safety management system in Korea is composed of four parts: rapid response system, AEFI surveillance system, AEFI investigation system, and vaccine injury compensation program (VICP) (Fig. 1) 5  2003  25  24  -1  2004  45  32  1  12  2005  364  352  3  9  2006  635  634  -1  2007  515  509  -6  2008  407  397  -10  2009  2,380  2,365  -15  2010  741  731  1  9  Total  5,339  5,232  10  97 The reported, diseases, disabled, and death cases are without epidemiological information and causality assessment is not made. 
AEFI.
When an AEFI has occurred, the vaccinees or their guardians may report the suspected AEFI through telephone to the local public health center; or by accessing website at http:// nip.cdc.go.kr; and the healthcare professionals may report through telephone to the local public health center; or by accessing website at http://is.cdc.go.kr. When the local public health center receives the notification of suspected AEFI, then they report to the KCDC through website or by telephone. KCDC then compile the nationally-collected AEFI data, analyze the unexpected pattern of AEFI, and conducts overall management of vaccine safety in Korea.
Case-Based AEFI Investigation
Thorough investigation and clear description of serious AEFI quell unnecessary concerns regarding vaccine safety. However, the quality of data collected by the routine surveillance system is limited because data collected do not include detailed epidemiological or clinical information regarding AEFI.
In 2011, KCDC initiated to retrospectively investigate the vaccination-related serious AEFI of seasonal trivalent influenza in Korea from 2003 to 2010 [16] . During the period, 42 potentially serious AEFI were reported. Of those, nine Guillain-Barré syndrome (GBS), eighteen other neurologic events, eight local events, and seven miscellaneous events were included (Table 3) . When classified according to causality assessment made by Korea Advisory Committee on Vaccine Injury Compensation for GBS, three were considered to be potentially associated to vaccination, whereas five were assessed as unlikely related. All of the three cellulitis cases had their injury sites that are not within 20 cm apart from the injection site, and two of the three cases had their symptoms onset after more than 2 weeks after vaccination. Approximately two third of localized events were assessed to have potential association with vaccination (62.5%, 5/8), whereas more than half of neurologic events (14/18) were considered to have no association with vaccination (unlikely).
In addition, ascertainment of each investigated cases is also important. In 2009-2010 season, mass vaccination for H1N1 pandemic influenza raised concern in a particular AEFI: the GBS. In 2011, KCDC investigated the data of reported cases of GBS following receipt of pandemic influenza vaccine in Korea [17] . All cases were reviewed under case definition developed by Brighton Collaboration Working Group, in order to ascertain a clear and precise case definition for AEFI data analysis. Of 29 reported cases during 2009-2010 season, 22 were confirmed to meet Brighton criteria level 1, 2, or 3 for GBS. Of those, 2 (9.1%) met level 1, 9 (40.9%) met level 2, and 11 (50.0%) met level 3. The Brighton case definition was used to improve the quality of AEFI data, and was applicable in retrospective review of medical records in cases with GBS after influenza A (H1N1) vaccination.
Vaccine Injury Compensation Program
The compensation of vaccine injury was meant to decrease the negative public awareness on vaccine safety may decrease the population vaccination coverage, which then consequently decreases the population immunity. The Korea National Vaccine Injury Compensation Program (KVICP), which was established in 1994, compensates individuals who experience certain AEFI for vaccines that are recommended by the government. The program was first became a legal entity under the Prevention of Contagious Disease Act in 1994, and consists of Committee with a chairperson and specialists in pediatric, neurology, cardiology, epidemiology, forensic medicine, and pharmaceutical engineering. In order to be eligible for compensation, a claim must be filed within 5 years after occurrence of AEFI, and the patient must have spent more than KRW300,000 (approximately US$300) on health care expenses. Table 4 depicts the annual number of potential adverse reactions that filed claim on VICP, and the number of cases compensated. Overall, nearly half of the cases were compen- sated (48.6%). The proportion of compensation ranged from 25% (1996) to 100% (2004) . Although the number of reported cases of AEFI has gradually increased during the last 10 years, the number of claims remained relatively constant during the same time-period (Table 4) . When a patient places a claim for compensation, the AEFI investigation team jointly operated by KCDC and local health authority starts an investigation. Determination of causal association between the injury and influenza vaccination is assessed by Korea Advisory Committee on Vaccine Injury Compensation, who use the simplified World Health Organization (WHO) categories of likelihood of causality: 1) definite, 2) probable, 3) possible, and 4) unlikely [18] . Compensations are made for cases that are classified as definite, probable, or possible.
Conclusion
The data collection and analysis of information on AEFI from the Korean AEFI surveillance system are continuously done. However, low reporting rate and limited data have prompted the introduction of supplementary surveillance measures to complete the data required to ensure vaccine safety in Korea. Further efforts will be needed to provide adequate data to ensure the safety of vaccines and immunizations currently practiced in the country. Many surveillance measures that are routinely performed or ad-hoc surveillance had showed the safety of vaccines currently utilized. Continual monitoring for AEFI is necessary to ensure the long-term safety of the vaccines, and to further contribute to vaccine policy for control of vaccine-preventable diseases and its complications in Korea.
